For the quarter ending 2025-09-30, SLXNW had $5,781K increase in cash & cash equivalents over the period. -$2,843K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -3,262 | -4,238 |
| Depreciation | 4 | 7 |
| Share-based payment arrangement, noncash expense | 38 | 58 |
| Other noncash income (expense) | -294 | - |
| Other noncash expense | - | 310 |
| Loss from lease termination | 0 | - |
| Increase in prepaid expenses | 56 | 717 |
| Decrease (increase) in other current assets | -16 | 1 |
| Increase (decrease) in accounts payable, trade | 254 | -237 |
| Increase (decrease) in operating lease liability | -2 | 1 |
| Increase (decrease) in employee related liabilities | 93 | -14 |
| Increase (decrease) in other accounts payable and accrued liabilities | 88 | -129 |
| Net cash provided by (used in) operating activities | -2,843 | -4,960 |
| Purchase of property and equipment | 0 | 7 |
| Net cash provided by (used in) investing activities | 0 | -7 |
| Proceeds from issuance of common stock | 0 | - |
| Cash acquired in excess of payments to acquire business | 0 | - |
| Proceeds from stock options exercised | - | 0 |
| Represents proceeds from issuance of ordinary shares upon public offering | 6,000 | 5,000 |
| Proceeds from issuance initial public offering | -653 | -745 |
| Proceeds from warrant exercises | 1,780 | 864 |
| Represents proceeds from issuance of ordinary shares upon warrants inducement | 1,760 | 3,276 |
| Issuance costs related to warrants inducement transactions | 232 | 462 |
| Represent the value of payment of underwriters promissory note | 0 | -696 |
| Represents the amount of prepaid of issuance cost related to at the market offering | 31 | - |
| Net cash provided by (used in) financing activities | 8,624 | 7,237 |
| Cash, cash equivalents, restricted cash, and restricted cash equivalents, period increase (decrease), excluding exchange rate effect | 5,781 | 2,270 |
| Effect of exchange rate changes on cash | 3 | - |
| Cash and cash equivalents at beginning of period | 1,270 | - |
| Cash and cash equivalents at end of period | 9,324 | - |
Silexion Therapeutics Corp (SLXNW)
Silexion Therapeutics Corp (SLXNW)